Cargando…
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma
Since the approval of sorafenib for the treatment of unresectable hepatocellular carcinoma in 2007 (in 2009 in Japan), five more regimens have been approved: lenvatinib, and atezolizumab plus bevacizumab for first-line treatment, and regorafenib, cabozantinib, and ramucirumab for second-line treatme...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Nature Singapore
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209396/ https://www.ncbi.nlm.nih.gov/pubmed/35527313 http://dx.doi.org/10.1007/s10147-022-02166-0 |